GlobeNewswire Inc | Jan 6, 2021 08:30AM EST

January 06, 2021

MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.:

-- 39th Annual J.P. Morgan Healthcare ConferenceWednesday, January 13 at 11:40 a.m. Eastern Time -- H.C. Wainwright Virtual BioConnect ConferenceOn-demand presentation available beginning Monday, January 11 at6:00 a.m.Eastern Time

-- Clinical Trial Panel Discussion at the H.C. Wainwright Virtual BioConnect ConferenceMonday, January 11 at12:00 p.m.Eastern Time

Live audio webcasts of the J.P. Morgan presentation and H.C. Wainwright Clinical Trials Panel and on-demand presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Replays of both the J.P. Morgan and H.C. Wainwright presentations will be available on the Company's website for two weeks following the respective presentation dates.

AboutChemoCentryx

ChemoCentryxis a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer.ChemoCentryxtargets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryxs lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by theU.S. Food and Drug Administration, along with a Marketing Authorization Application by theEuropean Medicines Agency. Avacopan is also in late-stage clinical development for the treatment of Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryxalso has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. KanayaExecutive Vice President,Chief Financial and Administrative Officerinvestor@chemocentryx.com

Media: Stephanie Tomei408.234.1279media@chemocentryx.com

Investors:Lee Roth, Burns McClellan212.213.0006 lroth@burnsmc.com